News >

Research Underway to Cure Locally Advanced Urothelial Carcinoma

Gina Columbus @ginacolumbusonc
Published: Tuesday, Oct 31, 2017

Elizabeth Plimack, MD

Elizabeth Plimack, MD
An ongoing phase II clinical trial is exploring the efficacy of risk-adapted treatment for patients with muscle-invasive bladder cancer after receiving a neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) regimen (NCT02710734). Researchers are hoping that this strategy will lead to bladder preservation as well as an improvement in quality of life, explained Elizabeth Plimack, MD.

State of the Science SummitTM on Renal Cell Carcinoma and Bladder Cancer, Plimack, who is chief of the Division of Genitourinary Medical Oncology at Fox Chase Cancer Center, spoke on the management of locally advanced urothelial carcinoma and the ongoing trials that are investigating treatments for this patient population.

OncLive: What did you discuss in your presentation?

Plimack: I was invited to talk about one of my favorite topics, which is the management of locally advanced urothelial cancer. This is bladder cancer that has just made its way into the muscle layer of the bladder, but has not extended beyond that. It is a high-risk situation where, for many patients, if left untreated, it would progress to metastatic disease and [they would] die of their disease. However, it also presents an opportunity for us to cure patients. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Medical Crossfire®: Treating MS in the Modern Era: Right Patient, Right Treatment, Right TimeApr 20, 20201.5
Publication Bottom Border
Border Publication
x